Synopsis
Synopsis
0
EU WC
0
KDMF
0
FDA Orange Book
DRUG PRODUCT COMPOSITIONS
0
US Patents
0
US Exclusivities
0
Health Canada Patents
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers


1. Dextran
2. Dextran 40000
3. Dextran 70
4. Dextran 75
5. Dextran 80
6. Dextran B 1355
7. Dextran B 1355 S
8. Dextran B-1355
9. Dextran B-1355-s
10. Dextran B1355
11. Dextran B512
12. Dextran Derivatives
13. Dextran M 70
14. Dextran T 40
15. Dextran T 500
16. Dextran T 70
17. Dextran T-40
18. Dextran T-500
19. Dextrans
20. Hemodex
21. Hyskon
22. Infukoll
23. Macrodex
24. Polyglucin
25. Promit
26. Rheodextran
27. Rheoisodex
28. Rheomacrodex
29. Rheopolyglucin
30. Rondex
31. Saviosol
1. L3l3xyp7mp
2. Lmwd
3. Schembl206877
4. Chembl1697742
5. O-alpha-d-glucopyranosyl-(1.6)-o-alpha-d-glucopyranosyl-(1.6)-d-glucose
6. Hy-n0913a
7. Dtxsid701317190
8. 6-.alpha.-isomaltosylglucose
9. Zinc64622163
10. Cs-0109495
11. D-glucose, O-.alpha.-d-glucopyranosyl-(1->6)-o-.alpha.-d-glucopyranosyl-(1->6)-
12. O-alpha-d-glucopyranosyl-(1-->6)-o-alpha-d-glucopyranosyl-(1-->6)-d-glucose
13. Wurcs=2.0/2,3,2/[o2122h][a2122h-1a_1-5]/1-2-2/a6-b1_b6-c1
14. (2r,3s,4r,5r)-2,3,4,5-tetrahydroxy-6-(((2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-((((2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl)oxy)methyl)oxan-2-yl)oxy)hexanal
| Molecular Weight | 504.4 g/mol |
|---|---|
| Molecular Formula | C18H32O16 |
| XLogP3 | -7.2 |
| Hydrogen Bond Donor Count | 11 |
| Hydrogen Bond Acceptor Count | 16 |
| Rotatable Bond Count | 11 |
| Exact Mass | 504.16903493 g/mol |
| Monoisotopic Mass | 504.16903493 g/mol |
| Topological Polar Surface Area | 277 Ų |
| Heavy Atom Count | 34 |
| Formal Charge | 0 |
| Complexity | 625 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 14 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 1 |
Anticoagulants
Agents that prevent BLOOD CLOTTING. (See all compounds classified as Anticoagulants.)
Plasma Substitutes
Any liquid used to replace blood plasma, usually a saline solution, often with serum albumins, dextrans or other preparations. These substances do not enhance the oxygen- carrying capacity of blood, but merely replace the volume. They are also used to treat dehydration. (See all compounds classified as Plasma Substitutes.)
SWATI - Transforming science into solutions with 60+ years of expertise, global accreditations, and pioneering biotech innovation.
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 19584
Submission : 2006-06-30
Status : Active
Type : II
Certificate Number : R1-CEP 1999-063 - Rev 03
Issue Date : 2022-01-03
Type : Chemical
Substance Number : 999
Status : Valid
NDC Package Code : 49442-5600
Start Marketing Date : 2015-07-01
End Marketing Date : 2026-12-31
Dosage Form (Strength) : POWDER (1g/g)
Marketing Category : BULK INGREDIENT

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others
USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 353
Submission : 1959-11-16
Status : Inactive
Type : II

Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others
USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 462
Submission : 1962-01-08
Status : Inactive
Type : II

Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others
USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 2573
Submission : 1975-12-03
Status : Inactive
Type : II

Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others
USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 9447
Submission : 1991-12-05
Status : Inactive
Type : II

Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 1183
Submission : 1968-05-07
Status : Inactive
Type : II

GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 1184
Submission : 1968-05-07
Status : Inactive
Type : II

Certificate Number : R1-CEP 1999-064 - Rev 03
Issue Date : 2022-01-03
Type : Chemical
Substance Number : 1000
Status : Valid
NDC Package Code : 49442-5800
Start Marketing Date : 2015-06-01
End Marketing Date : 2026-12-31
Dosage Form (Strength) : POWDER (1g/g)
Marketing Category : BULK INGREDIENT

Certificate Number : R1-CEP 1999-065 - Rev 03
Issue Date : 2022-01-03
Type : Chemical
Substance Number : 1001
Status : Valid
NDC Package Code : 49442-5001
Start Marketing Date : 2011-11-01
End Marketing Date : 2026-12-31
Dosage Form (Strength) : POWDER (100g/100g)
Marketing Category : DRUG FOR FURTHER PROCESSING

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 1184
Submission : 1968-05-07
Status : Inactive
Type : II

GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 1183
Submission : 1968-05-07
Status : Inactive
Type : II

GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 19584
Submission : 2006-06-30
Status : Active
Type : II

USDMF
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 2573
Submission : 1975-12-03
Status : Inactive
Type : II

Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
USDMF
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 462
Submission : 1962-01-08
Status : Inactive
Type : II

Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
USDMF
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 9447
Submission : 1991-12-05
Status : Inactive
Type : II

Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
USDMF
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 353
Submission : 1959-11-16
Status : Inactive
Type : II

Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Certificate Number : R1-CEP 2003-165 - Rev 01
Status : Valid
Issue Date : 2022-01-03
Type : Chemical
Substance Number : 1506

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Certificate Number : R1-CEP 1999-065 - Rev 03
Status : Valid
Issue Date : 2022-01-03
Type : Chemical
Substance Number : 1001

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Certificate Number : R1-CEP 1999-064 - Rev 03
Status : Valid
Issue Date : 2022-01-03
Type : Chemical
Substance Number : 1000

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Certificate Number : R1-CEP 1999-063 - Rev 03
Status : Valid
Issue Date : 2022-01-03
Type : Chemical
Substance Number : 999

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] Registration Number : 217MF11169
Registrant's Address : 41, 2-chome, Sasazuka-cho, Nishi-ku, Nagoya City, Aichi Prefecture
Initial Date of Registration : 2005-12-12
Latest Date of Registration : 2018-10-01

Dextran sulfate sodium sulfur 18
Registration Number : 218MF10826
Registrant's Address : 2-41 Sasazuka-cho, Nishi-ku, Nagoya City, Aichi Prefecture
Initial Date of Registration : 2006-10-20
Latest Date of Registration : 2006-10-20

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]NDC Package Code : 49442-5040
Start Marketing Date : 2006-09-01
End Marketing Date : 2026-12-31
Dosage Form (Strength) : POWDER (1g/g)
Marketing Category : BULK INGREDIENT

NDC Package Code : 49442-5070
Start Marketing Date : 2011-11-01
End Marketing Date : 2026-12-31
Dosage Form (Strength) : POWDER (100g/100g)
Marketing Category : DRUG FOR FURTHER PROCESSING

NDC Package Code : 49442-5060
Start Marketing Date : 2011-11-01
End Marketing Date : 2026-12-31
Dosage Form (Strength) : POWDER (100g/100g)
Marketing Category : DRUG FOR FURTHER PROCESSING

NDC Package Code : 49442-5001
Start Marketing Date : 2011-11-01
End Marketing Date : 2026-12-31
Dosage Form (Strength) : POWDER (100g/100g)
Marketing Category : DRUG FOR FURTHER PROCESSING

NDC Package Code : 49442-5600
Start Marketing Date : 2015-07-01
End Marketing Date : 2026-12-31
Dosage Form (Strength) : POWDER (1g/g)
Marketing Category : BULK INGREDIENT

NDC Package Code : 49442-5800
Start Marketing Date : 2015-06-01
End Marketing Date : 2026-12-31
Dosage Form (Strength) : POWDER (1g/g)
Marketing Category : BULK INGREDIENT

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]VMF Number : 336
Submission : 1959-05-18
Status : Active
Type : II

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
SWATI - Transforming science into solutions with 60+ years of expertise, global accreditations, and pioneering biotech innovation.
About the Company : Swati Spentose Pvt. Ltd. (SSPL), part of the 60-year-old V Group, is a globally trusted pharmaceutical manufacturer supplying to 70+ countries. We specialize in high-quality APIs a...
About the Company : PT. Cahaya Mandiri Farma is a leading company in the pharmaceutical industry, dedicated to producing high-quality healthcare products for humans. We are committed to excellence thr...

About the Company : Xi'an Wanlong Pharmaceutical Co., Ltd was founded in 1995 and it is comprehensive modern pharmaceutical enterprise which mainly produces formulations, API and intermediates, GMP & ...

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Related Excipient Companies
Excipients by Applications
Global Sales Information
Market Place
Reply
23 Sep 2021
Reply
25 Aug 2021
Reply
06 Oct 2020
Reply
16 Jun 2020
Reply
19 Oct 2018
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
REF. STANDARDS & IMPURITIES
ABOUT THIS PAGE
27
PharmaCompass offers a list of Dextrans API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, and more, enabling you to easily find the right Dextrans manufacturer or Dextrans supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Dextrans manufacturer or Dextrans supplier.
A Dextran 40 manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Dextran 40, including repackagers and relabelers. The FDA regulates Dextran 40 manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Dextran 40 API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of Dextran 40 manufacturers with USDMF, JDMF, KDMF, CEP, GMP, and COA related information on PhamaCompass.
A Dextran 40 supplier is an individual or a company that provides Dextran 40 active pharmaceutical ingredient (API) or Dextran 40 finished formulations upon request. The Dextran 40 suppliers may include Dextran 40 API manufacturers, exporters, distributors and traders.
click here to find a list of Dextran 40 suppliers with USDMF, JDMF, KDMF, CEP, GMP, and COA related information on PharmaCompass.
A Dextran 40 DMF (Drug Master File) is a document detailing the whole manufacturing process of Dextran 40 active pharmaceutical ingredient (API) in detail. Different forms of Dextran 40 DMFs exist exist since differing nations have different regulations, such as Dextran 40 USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A Dextran 40 DMF submitted to regulatory agencies in the US is known as a USDMF. Dextran 40 USDMF includes data on Dextran 40's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The Dextran 40 USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of Dextran 40 suppliers with USDMF on PharmaCompass.
The Pharmaceuticals and Medical Devices Agency (PMDA) established the Japan Drug Master File (JDMF), also known as the Master File (MF), to permit Japanese and foreign manufacturers of drug substances, intermediates, excipients, raw materials, and packaging materials (‘Products’) to voluntarily register confidential information about the production and management of their products in Japan.
The Dextran 40 Drug Master File in Japan (Dextran 40 JDMF) empowers Dextran 40 API manufacturers to present comprehensive information (e.g., production methods, data, etc.) to the review authority, i.e., PMDA (Pharmaceuticals & Medical Devices Agency).
PMDA reviews the Dextran 40 JDMF during the approval evaluation for pharmaceutical products. At the time of Dextran 40 JDMF registration, PMDA checks if the format is accurate, if the necessary items have been included (application), and if data has been attached.
click here to find a list of Dextran 40 suppliers with JDMF on PharmaCompass.
A Dextran 40 CEP of the European Pharmacopoeia monograph is often referred to as a Dextran 40 Certificate of Suitability (COS). The purpose of a Dextran 40 CEP is to show that the European Pharmacopoeia monograph adequately controls the purity of Dextran 40 EP produced by a given manufacturer. Suppliers of raw materials can prove the suitability of Dextran 40 to their clients by showing that a Dextran 40 CEP has been issued for it. The manufacturer submits a Dextran 40 CEP (COS) as part of the market authorization procedure, and it takes on the role of a Dextran 40 CEP holder for the record. Additionally, the data presented in the Dextran 40 CEP (COS) is managed confidentially and offers a centralized system acknowledged by numerous nations, exactly like the Dextran 40 DMF.
A Dextran 40 CEP (COS) is recognised by all 36 nations that make up the European Pharmacopoeia Convention. Dextran 40 CEPs may be accepted in nations that are not members of the Ph. Eur. at the discretion of the authorities there.
click here to find a list of Dextran 40 suppliers with CEP (COS) on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Dextran 40 as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for Dextran 40 API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture Dextran 40 as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain Dextran 40 and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Dextran 40 NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of Dextran 40 suppliers with NDC on PharmaCompass.
Dextran 40 Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Dextran 40 GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, and more, enabling you to easily find the right Dextran 40 GMP manufacturer or Dextran 40 GMP API supplier for your needs.
A Dextran 40 CoA (Certificate of Analysis) is a formal document that attests to Dextran 40's compliance with Dextran 40 specifications and serves as a tool for batch-level quality control.
Dextran 40 CoA mostly includes findings from lab analyses of a specific batch. For each Dextran 40 CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Dextran 40 may be tested according to a variety of international standards, such as European Pharmacopoeia (Dextran 40 EP), Dextran 40 JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Dextran 40 USP).